Colchicine: Effect, Gout & Pericarditis
Colchicine is an alkaloid extracted from the autumn crocus (Colchicum autumnale) that has been used in medicine for over 3,000 years. Originally derived from ancient Egyptian and Greek medicine for joint pain, colchicine today has a precisely defined mechanism of action and established roles in the treatment of gout, familial Mediterranean fever, and pericarditis.
Despite its long history, colchicine remains highly relevant in modern medicine. Recent large-scale cardiovascular outcome trials have demonstrated that low-dose colchicine reduces the risk of major adverse cardiovascular events, opening potential new indications in cardiology. The narrow therapeutic window and complex interaction profile require careful clinical management.
Mechanism of Action
Colchicine binds to tubulin, the building block of microtubules, and prevents their polymerization. This disrupts the cytoskeleton of cells, particularly affecting neutrophil granulocytes. In gout, neutrophils migrate into the joint space attracted by urate crystals and release inflammatory mediators. Colchicine impairs neutrophil migration, degranulation, and NLRP3 inflammasome activation, thereby interrupting the inflammatory cascade triggered by urate crystals. Unlike NSAIDs, colchicine does not inhibit cyclooxygenase and does not reduce prostaglandin synthesis.
Indications
Colchicine is approved for acute gout attacks and prophylaxis of recurrent gout flares, for familial Mediterranean fever (FMF) including prevention of amyloidosis, and for acute and recurrent pericarditis. Low-dose colchicine (0.5 mg daily, brand name Lodoco) has received regulatory approval in several countries for reduction of cardiovascular risk in patients with established coronary artery disease or multiple cardiovascular risk factors. Off-label use includes Behcet's disease and other autoinflammatory syndromes.
Dosage and Administration
For acute gout: initial dose of 1 mg followed by 0.5 mg one hour later on day one, then 0.5 mg twice daily until the attack resolves. For gout prophylaxis: 0.5 mg once or twice daily. For pericarditis: 0.5 mg twice daily (patients under 70 kg or intolerant: 0.5 mg once daily) for three months in first episode, six months in recurrent pericarditis, typically combined with anti-inflammatory drugs in the first weeks. For FMF: 0.5 to 2.0 mg daily individualized to attack frequency and tolerability. Dose reduction is mandatory in renal and hepatic impairment.
Side Effects
Gastrointestinal effects are the most common adverse reactions: diarrhea, nausea, vomiting, and abdominal pain affect a significant proportion of patients and are dose-dependent. Reducing the dose usually resolves these symptoms. Neuromuscular toxicity including myopathy and neuropathy can occur with long-term use, particularly in elderly patients or those with renal insufficiency. Bone marrow suppression is rare but serious, presenting as leukopenia, thrombocytopenia, or aplastic anemia. Alopecia has been reported with long-term use. Colchicine overdose is potentially fatal; the therapeutic window is narrow.
Interactions
Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir) and P-glycoprotein inhibitors (cyclosporine, verapamil) can increase colchicine plasma concentrations several-fold, leading to severe toxicity. In patients taking these drugs, colchicine dose must be reduced or the combination avoided. Statins combined with colchicine increase the risk of myopathy. HMG-CoA reductase inhibitors and fibrates may enhance neuromuscular toxicity. NSAIDs combined with colchicine may increase gastrointestinal adverse effects.
Special Notes
Colchicine is a prescription-only medicine with a narrow therapeutic index. Overdose can be life-threatening without an available specific antidote; supportive treatment in an intensive care unit may be necessary. Patients with severe renal impairment (eGFR below 30 mL/min) should not receive colchicine long-term. Colchicine is contraindicated during pregnancy as it is teratogenic; reliable contraception is required. Men taking colchicine should be advised that it may reduce sperm motility, though this effect is generally reversible after discontinuation. Regular blood count and renal function monitoring is recommended for long-term users.
Related Topics
Frequently Asked Questions
Can colchicine be taken long-term?
Yes, long-term use is established for gout prophylaxis and familial Mediterranean fever. Regular monitoring of blood count and kidney function is required. Dose adjustment is necessary when kidney function declines.
Why is colchicine not allowed with clarithromycin?
Clarithromycin inhibits CYP3A4 and P-glycoprotein, two of the main elimination pathways for colchicine. The combination can increase colchicine blood levels four to sixfold, leading to severe gastrointestinal, neuromuscular, and bone marrow toxicity. The combination is contraindicated or requires significant dose reduction.
Does colchicine affect the heart?
Colchicine itself does not have direct cardiac effects. However, the COLCOT and LoDoCo2 trials showed that low-dose colchicine reduces the risk of heart attacks and strokes in patients with coronary artery disease, likely through anti-inflammatory mechanisms. This cardiovascular indication is now approved in some countries.
Sources
- Imazio M et al: COPE Trial Colchicine Pericarditis. N Engl J Med 2023
- Tardif JC et al: COLCOT Trial. N Engl J Med 2019
- ESC Pericardial Disease Guidelines 2022